Portola Pharmaceuticals Inc, South San Francisco (United States of America)
Follow
Contributor content
Presentation
Reversal of apixaban and rivaroxaban anticoagulation by andexanet alfa in ANNEXA-A&R as assessed by non-tissue factor (TF)-initiated thrombin generation independent of TF pathway inhibitor (TFPI)
